Related News for Cyfuse Biomedical K.K.

Executive Summary Cyfuse Biomedical K.K. (Securities Code: 4892), a developer of

The Q2 FY2026 earnings for Cyfuse Biomedical K.K. (Securities Code: 4892), a regener

Cyfuse (4892) has released its financial results, reporting a significant top-line expansion with revenue reaching 104 million yen, representing a substantial increase of +254.6% year-over-year. Meanw